Stent Coating Apparatus with Fibers

ABSTRACT

A stent coating apparatus for coating a stent includes a brush assembly, a stent support, and a dispensing mechanism. The brush assembly includes a plurality of fibers, and the stent support carries a stent at a position in which the stent is in contact with the fibers. The dispensing mechanism dispenses a coating composition to the plurality of fibers.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of application Ser. No. 12/510,121,filed on Jul. 27, 2009, now U.S. Pat. No. 8,394,447, which is a divisionof application Ser. No. 10/999,829, filed Nov. 29, 2004, now U.S. Pat.No. 7,588,642, both of which applications are incorporated herein byreference.

TECHNICAL FIELD

This invention relates generally to stent coating apparatuses, and moreparticularly, but not exclusively, provides a brush assembly and methodfor coating of an abluminal stent surface.

BACKGROUND

Blood vessel occlusions are commonly treated by mechanically enhancingblood flow in the affected vessels, such as by employing a stent. Stentsact as scaffoldings, functioning to physically hold open and, ifdesired, to expand the wall of affected vessels. Typically stents arecapable of being compressed, so that they can be inserted through smalllumens via catheters, and then expanded to a larger diameter once theyare at the desired location. Examples in the patent literaturedisclosing stents include U.S. Pat. No. 4,733,665 issued to Palmaz, U.S.Pat. No. 4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062issued to Wiktor.

FIG. 1 illustrates a conventional stent 10 formed from a plurality ofstruts 12. The plurality of struts 12 are radially expandable andinterconnected by connecting elements 14 that are disposed betweenadjacent struts 12, leaving lateral openings or gaps 16 between adjacentstruts 12. The struts 12 and the connecting elements 14 define a tubularstent body having an outer, tissue-contacting surface and an innersurface.

Stents are being modified to provide drug delivery capabilities. Apolymeric carrier, impregnated with a drug or therapeutic substance iscoated on a stent. The conventional method of coating is by, forexample, applying a composition including a solvent, a polymer dissolvedin the solvent, and a therapeutic substance dispersed in the blend tothe stent by immersing the stent in the composition or by spraying thecomposition onto the stent. The solvent is allowed to evaporate, leavingon the stent strut surfaces a coating of the polymer and the therapeuticsubstance impregnated in the polymer. The dipping or spraying of thecomposition onto the stent can result in a complete coverage of allstent surfaces, i.e., both luminal (inner) and abluminal (outer)surfaces, with a coating. However, having a coating on the luminalsurface of the stent can have a detrimental impact on the stent'sdeliverability as well as the coating's mechanical integrity. Moreover,from a therapeutic standpoint, the therapeutic agents on an innersurface of the stent get washed away by the blood flow and typically canprovide for an insignificant therapeutic effect. In contrast, the agentson the outer surfaces of the stent are in contact with the lumen, andprovide for the delivery of the agent directly to the tissues. Polymersof a stent coating also elicit a response from the body. Reducing theamount to foreign material can only be beneficial.

Briefly, an inflatable balloon of a catheter assembly is inserted into ahollow bore of a coated stent. The stent is securely mounted on theballoon by a crimping process. The balloon is inflated to implant thestent, deflated, and then withdrawn out from the bore of the stent. Apolymeric coating on the inner surface of the stent can increase thecoefficient of friction between the stent and the balloon of a catheterassembly on which the stent is crimped for delivery. Additionally, somepolymers have a “sticky” or “tacky” consistency. If the polymericmaterial either increases the coefficient of friction or adherers to thecatheter balloon, the effective release of the stent from the balloonafter deflation can be compromised. If the stent coating adheres to theballoon, the coating, or parts thereof, can be pulled off the stentduring the process of deflation and withdrawal of the balloon followingthe placement of the stent. Adhesive, polymeric stent coatings can alsoexperience extensive balloon sheer damage post-deployment, which couldresult in a thrombogenic stent surface and possible embolic debris. Thestent coating can stretch when the balloon is expanded and maydelaminate as a result of such shear stress.

Another shortcoming of the spray coating and immersion methods is thatthese methods tend to from defects on stents, such as webbing betweenadjacent stent struts 12 and connecting elements 14 and the pooling orclumping of coating on the struts 12 and/or connecting elements 14. Inaddition, spray coating can cause coating defects at the interfacebetween a stent mandrel and the stent 10 as spray coating will coat boththe stent 10 and the stent mandrel at this interface, possibly forming aclump. During removal of the stent 10 from the stent mandrel, this clumpmay detach from the stent 10, thereby leaving an uncoated surface on thestent 10. Alternatively, the clump may remain on the stent 10, therebyyielding a stent 10 with excessive coating.

Accordingly, a new apparatus and method are needed to enable selectivecoating of stent surfaces while minimizing the formation of defects.

SUMMARY

Briefly and in general terms, the present invention is directed to astent coating apparatus.

In aspects of the present invention, a stent coating apparatus comprisesa brush assembly including a plurality of fibers, a stent supportconfigured to carry a stent at a position in which the stent is incontact with the plurality of fibers, and a dispensing mechanismconfigured to dispense a coating composition to the plurality of fibers.

In aspects of the present invention, a stent coating apparatus enablesselective coating of stent surfaces while avoiding coating defectscaused by conventional spray coating and immersion coating techniques.

In aspects of the present invention, a stent coating apparatus comprisesa dispensing mechanism, a brush assembly in fluid communication with thedispensing mechanism, and an optical feedback system. The dispensingmechanism dispenses a coating onto the brush assembly and the opticalfeedback system aligns the brush assembly with a stent strut such thatthe brush assembly coats the stent strut with the dispensed coating.

The features and advantages of the invention will be more readilyunderstood from the following detailed description which should be readin conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Non-limiting and non-exhaustive embodiments of the present invention aredescribed with reference to the following figures, wherein likereference numerals refer to like parts throughout the various viewsunless otherwise specified.

FIG. 1 is a diagram illustrating a conventional stent;

FIG. 2 is a block diagram illustrating a stent coating apparatusaccording to an embodiment of the invention;

FIG. 3 is a block diagram illustrating a stent coating apparatusaccording to another embodiment of the invention;

FIG. 4A, FIG. 4B, FIG. 4C, FIG. 4D, FIG. 4E, and FIG. 4F are diagramsillustrating brush assemblies of the stent coating apparatuses accordingto embodiments of the invention;

FIG. 5 is a diagram illustrating a brush assembly coating a stent strut;and

FIG. 6 is a flowchart illustrating a method of coating an abluminalstent surface.

DETAILED DESCRIPTION

The following description is provided to enable any person havingordinary skill in the art to make and use the invention, and is providedin the context of a particular application and its requirements. Variousmodifications to the embodiments will be readily apparent to thoseskilled in the art, and the generic principles defined herein may beapplied to other embodiments and applications without departing from thespirit and scope of the invention. Thus, the present invention is notintended to be limited to the embodiments shown, but is to be accordedthe widest scope consistent with the principles, features and teachingsdisclosed herein.

FIG. 2 is a block diagram illustrating a stent coating apparatus 200according to an embodiment of the invention. The apparatus 200,including a stent mandrel fixture 20 for supporting the stent 10, isillustrated to include a support member 22, a mandrel 24, and a lockmember 26. The support member 22 can connect to a motor 30A so as toprovide rotational motion about the longitudinal axis of the stent 10,as depicted by arrow 32, during a coating process. Another motor 30B canalso be provided for moving the support member 22 in a linear direction,back and forth, along a rail 34.

The support member 22 includes a coning end portion 36, taperinginwardly. In accordance with one embodiment of the invention, themandrel 24 can be permanently affixed to coning end portion 36.Alternatively, the support member 22 can include a bore 38 for receivinga first end of the mandrel 24. The first end of mandrel 24 can bethreaded to screw into the bore 38 or, alternatively, can be retainedwithin the bore 38 by a friction fit. The bore 38 should be deep enoughso as to allow the mandrel 24 to securely mate with the support member22. The depth of the bore 38 can also be over-extended so as to allow asignificant length of the mandrel 24 to penetrate or screw into the bore38. The bore 38 can also extend completely through the support member22. This would allow the length of the mandrel 24 to be adjusted toaccommodate stents of various sizes.

The lock member 26 includes a coning end portion 42 tapering inwardly. Asecond end of the mandrel 24 can be permanently affixed to the lockmember 26 if the first end is disengagable from the support member 22.Alternatively, in accordance with another embodiment, the mandrel 24 canhave a threaded second end for screwing into a bore 46 of the lockmember 26. The bore 46 can be of any suitable depth that would allow thelock member 26 to be incrementally moved closer to the support member22. The bore 46 can also extend completely through the lock member 26.Accordingly, the stents 10 of any length can be securely pinched betweenthe support and the lock members 22 and 26. In accordance with yetanother embodiment, a non-threaded second end and the bore 46combination is employed such that the second end can be press-fitted orfriction-fitted within the bore 46 to prevent movement of the stent 10on the stent mandrel fixture 20.

Positioned a distance from the stent 10 (e.g., above the stent 10) is areservoir 210 holding a coating substance to be applied to the stent 10.The reservoir 210 is in fluid communication with a needle or otherdispensing mechanism 220, which is in fluid communication with a brushassembly 230. In an embodiment of the invention, an atomizer 240 can becoupled to the needle 220 and provides atomizing air to the needle 220for atomizing the coating substance before it is dispensed.

The reservoir 210 dispenses the coating substance to the needle 220,which dispenses it to the brush assembly 230, which will be discussed infurther detail in conjunction with FIG. 4A-4F below. The reservoir 210can dispense the coating substance using gravity and/or forced pressure(e.g., a pump). The use of forced pressure enables the accurate controlof the amount of coating substance dispensed. The force must be highenough to allow for the adequate coating of the stent 10 but cannot tobe too high such that it leads to non-uniform coating of the stent 10.The reservoir 210 can dispense the coating at a constant rate, at avariable rate, or intermittently. For example, during the application ofthe coating substance, the rate of coating dispensed can be adjusted sothat certain sections of the stent 10 receive more coating than others.If the coating material is applied in an intermittent fashion, coatingadjustments can be made during the stoppage of coating application.Further, the coating can be stopped while the brush assembly 230 isbeing repositioned relative to the stent 10. Negative pressure can beapplied to the brush assembly 230 to prevent the coating frominadvertently dripping onto the stent 10.

The brush assembly 230 is aligned with a stent strut 12 and coats eachindividual stent strut 12. As will be discussed further below inconjunction with FIG. 5, coating flows from the needle 220 to and alongthe brush assembly 230 onto the stent strut 12, thereby limiting thecoating to just the outer surface stent strut 12 and not other surfaces(e.g., the luminal surface) as in spaying and immersion techniques. Inone embodiment, the sidewalls of the stent struts 12 between the outerand inner surfaces can be partially coated. Partial coating of sidewallscan be incidental, such as that some coating can flow from the outersurface onto the sidewalls. In some embodiments coating of sidewalls canbe intentional, such that the brush is designed to deposit coating onthe other surfaces. In some embodiment, the brush is designed tocompletely coat all of the sidewalls of the struts 12.

Coupled to the needle 220 can be a first imaging device 250 that imagesthe stent 10 before and/or after the coating substance has been appliedto a portion of the stent 10. The first imaging device 250, along with asecond imaging device 260 located a distance from the stent 10, are bothcommunicatively coupled to an optical feedback system 270 via wired orwireless techniques. The reservoir 210 and the atomizer 240 may also becommunicatively coupled to the optical feedback system 270 via wired orwireless techniques. Based on the imagery provided by the imagingdevices 250 and 260, the optical feedback system 270 controls movementof stent 10 via the motors 30A and 30B to keep the brush assembly 230aligned with the stent struts 12 and recoat the stent struts 12 ifimproperly (or inadequately) coated.

During operation of the stent coating apparatus 200, the opticalfeedback system 270 causes the imaging device 260 to image the fullsurface of the stent 10 as the feedback system 270 causes the motor 30Ato rotate the stent 10. After the initial imaging, the optical feedbacksystem 270, using the imaging device 260, aligns the brush assembly 230with a stent strut 12 by causing the engines 30A and 30B to rotate andtranslate the stent 10 until alignment is achieved. The optical feedbacksystem 270 then causes the reservoir 210 (e.g., through a pump mechanismknown to those of ordinary skill in the art) to dispense the coatingsubstance through the needle 220 to the brush assembly 230. As thecoating substance is dispensed, the optical feedback system 270 causesthe engines 30A and 30B to rotate and translate the stent 10 in relationto the brush assembly 230 so as to effective drag the stent strut 12along the brush assembly 230, thereby causing the strut 12 to be coated.In an embodiment of the invention, the optical feedback system 270 alsocause the atomizer 240 to atomize the coating substance as it is beingdispensed through the needle 220.

After a portion of the stent strut 12 has been coated, the opticalfeedback system 270 causes the reservoir 210 to cease dispensing thecoating substance and causes the imaging device 250 to image the stentstrut 12 to determine if the strut 12 has been adequately coated. Thisdetermination can be made by measuring the difference in color and/orreflectivity of the stent strut 12 before and after the coating process.If the strut 12 has been adequately coated, then the optical feedbacksystem 270 causes the engines 30A and 30B to rotate and translate thestent 10 so that the brush assembly 230 is aligned with an uncoatedstent 10 section and the above process is then repeated. If the stentstrut 12 is not coated adequately, then the optical feedback system 270causes the engines 30A and 30B to rotate and translate the stent 10 andthe reservoir 210 to dispense the coating substance to recoat the stentstrut 12. In another embodiment of the invention, the optical feedbacksystem 270 can cause checking and recoating of the stent 10 after theentire stent 10 is goes through a first coating pass.

In an embodiment of the invention, the imaging devices 250 and 260include charge coupled devices (CCDs) or complementary metal oxidesemiconductor (CMOS) devices. In an embodiment of the invention, theimaging devices 250 and 260 are combined into a single imaging device.Further, it will be appreciated by one of ordinary skill in the art thatplacement of the imaging devices 250 and 260 can vary as long as theyhave an acceptable view of the stent 10. In addition, one of ordinaryskill in the art will realize that the stent mandrel fixture 20 can takeany form or shape as long as it is capable of securely holding the stent10 in place.

Accordingly, embodiments of the invention enable the fine coating ofspecific surfaces of the stent 10, thereby avoiding coating defects thatcan occur with spray coating and immersion coating methods and limitingthe coating to only the abluminal surface and/or sidewalls of the stent10. Application of the coating in the gaps 16 between the stent struts12 can be partially, or preferable completely, avoided.

After the brush coating of the stent 10 abluminal surface, the stent 10can then have the inner surface coated via electroplating or spraycoating. Without masking the outer surface of the stent 10, bothelectroplating and spray coating may yield some composition onto theouter surface and sidewalls of the stent 10. However, the inner surfacewould be substantially solely coated with a single composition differentfrom the composition used to coat the outer surface of the stent 10.Accordingly, it will be appreciated by one of ordinary skill in the artthat this embodiment enables the coating of the inner surface and theouter surface of the stent 10 with different compositions. For example,the inner surface could be coated with a composition having abio-beneficial therapeutic substance for delivery downstream of thestent 10 (e.g., an anticoagulant, such as heparin, to reduce plateletaggregation, clotting and thrombus formation) while the outer surface ofthe stent 10 could be coating with a composition having a therapeuticsubstance for local delivery to a blood vessel wall (e.g., ananti-inflammatory drug to treat vessel wall inflammation or a drug forthe treatment of restenosis).

The components of the coating substance or composition can include asolvent or a solvent system comprising multiple solvents, a polymer or acombination of polymers, a therapeutic substance or a drug or acombination of drugs. In some embodiments, the coating substance can beexclusively a polymer or a combination of polymers (e.g., forapplication of a primer layer or topcoat layer). In some embodiments,the coating substance can be a drug that is polymer free. Polymers canbe biostable, bioabsorbable, biodegradable, or bioerodable. Biostablerefers to polymers that are not biodegradable. The terms biodegradable,bioabsorbable, and bioerodable are used interchangeably and refer topolymers that are capable of being completely degraded and/or erodedwhen exposed to bodily fluids such as blood and can be graduallyresorbed, absorbed, and/or eliminated by the body. The processes ofbreaking down and eventual absorption and elimination of the polymer canbe caused by, for example, hydrolysis, metabolic processes, bulk orsurface erosion, and the like.

Representative examples of polymers that may be used include, but arenot limited to, poly(N-acetylglucosamine) (Chitin), Chitoson,poly(hydroxyvalerate), poly(lactide-co-glycolide),poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate),polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolide),poly(L-lactic acid), poly(L-lactide), poly(D,L-lactic acid),poly(D,L-lactide), poly(D-lactic acid), poly(D-lactide),poly(caprolactone), poly(trimethylene carbonate), polyester amide,poly(glycolic acid-co-trimethylene carbonate), co-poly(ether-esters)(e.g. PEO/PLA), polyphosphazenes, biomolecules (such as fibrin,fibrinogen, cellulose, starch, collagen and hyaluronic acid),polyurethanes, silicones, polyesters, polyolefins, polyisobutylene andethylene-alphaolefin copolymers, acrylic polymers and copolymers otherthan polyacrylates, vinyl halide polymers and copolymers (such aspolyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether),polyvinylidene halides (such as polyvinylidene chloride),polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such aspolystyrene), polyvinyl esters (such as polyvinyl acetate),acrylonitrile-styrene copolymers, ABS resins, polyamides (such as Nylon66 and polycaprolactam), polycarbonates, polyoxymethylenes, polyimides,polyethers, polyurethanes, rayon, rayon-triacetate, cellulose, celluloseacetate, cellulose butyrate, cellulose acetate butyrate, cellophane,cellulose nitrate, cellulose propionate, cellulose ethers, andcarboxymethyl cellulose. Representative examples of polymers that may beespecially well suited for use include ethylene vinyl alcohol copolymer(commonly known by the generic name EVOH or by the trade name EVAL),poly(butyl methacrylate), poly(vinylidenefluoride-co-hexafluororpropene) (e.g., SOLEF 21508, available fromSolvay Solexis PVDF, Thorofare, N.J.), polyvinylidene fluoride(otherwise known as KYNAR, available from ATOFINA Chemicals,Philadelphia, Pa.), ethylene-vinyl acetate copolymers, and polyethyleneglycol.

“Solvent” is defined as a liquid substance or composition that iscompatible with the polymer and/or drug and is capable of dissolving thepolymer and/or drug at the concentration desired in the composition.Examples of solvents include, but are not limited to, dimethylsulfoxide,chloroform, acetone, water (buffered saline), xylene, methanol, ethanol,1-propanol, tetrahydrofuran, 1-butanone, dimethylformamide,dimethylacetamide, cyclohexanone, ethyl acetate, methylethylketone,propylene glycol monomethylether, isopropanol, isopropanol admixed withwater, N-methylpyrrolidinone, toluene, and mixtures and combinationsthereof.

The therapeutic substance or drug can include any substance capable ofexerting a therapeutic or prophylactic effect. Examples of active agentsinclude antiproliferative substances such as actinomycin D, orderivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 WestSaint Paul Avenue, Milwaukee, Wis. 53233; or COSMEGEN available fromMerck). Synonyms of actinomycin D include dactinomycin, actinomycin IV,actinomycin I₁, actinomycin X₁, and actinomycin C₁. The bioactive agentcan also fall under the genus of antineoplastic, anti-inflammatory,antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic,antibiotic, antiallergic and antioxidant substances. Examples of suchantineoplastics and/or antimitotics include paclitaxel, (e.g., TAXOL® byBristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g., Taxotere®,from Aventis S.A., Frankfurt, Germany), methotrexate, azathioprine,vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g.,Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g.,Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples ofsuch antiplatelets, anticoagulants, antifibrin, and antithrombinsinclude aspirin, sodium heparin, low molecular weight heparins,heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin andprostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone(synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa plateletmembrane receptor antagonist antibody, recombinant hirudin, and thrombininhibitors such as Angiomax ä (Biogen, Inc., Cambridge, Mass.). Examplesof such cytostatic or antiproliferative agents include angiopeptin,angiotensin converting enzyme inhibitors such as captopril (e.g.,Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.),cilazapril or lisinopril (e.g., Prinivil® and Prinzide® from Merck &Co., Inc., Whitehouse Station, N.J.), calcium channel blockers (such asnifedipine), colchicine, proteins, peptides, fibroblast growth factor(FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists,lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol loweringdrug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station,N.J.), monoclonal antibodies (such as those specific forPlatelet-Derived Growth Factor (PDGF) receptors), nitroprusside,phosphodiesterase inhibitors, prostaglandin inhibitors, suramin,serotonin blockers, steroids, thioprotease inhibitors,triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example ofan antiallergic agent is permirolast potassium. Other therapeuticsubstances or agents which may be appropriate agents include cisplatin,insulin sensitizers, receptor tyrosine kinase inhibitors, carboplatin,alpha-interferon, genetically engineered epithelial cells, steroidalanti-inflammatory agents, non-steroidal anti-inflammatory agents,antivirals, anticancer drugs, anticoagulant agents, free radicalscavengers, estradiol, antibiotics, nitric oxide donors, super oxidedismutases, super oxide dismutases mimics,4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO),tacrolimus, dexamethasone, ABT-578, clobetasol, cytostatic agents,prodrugs thereof, co-drugs thereof, and a combination thereof. Othertherapeutic substances or agents may include rapamycin and structuralderivatives or functional analogs thereof, such as40-O-(2-hydroxy)ethyl-rapamycin (everolimus),40-O-(3-hydroxy)propyl-rapamycin,40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

FIG. 3 is a block diagram illustrating a stent coating apparatus 300according to another embodiment of the invention. The stent coatingapparatus 300 is similar to the stent coating apparatus 200. However,the brush assembly 230 is capable of translational movement along aguide rail 310. Accordingly, the alignment of the brush assembly 230with a stent strut 12 is accomplished by the optical feedback system 270causing the engine 30A to rotate the stent 10 in combination withcausing the brush assembly 230 to move along the guard rail 310. Theguard rail 310 should be at least about as long as the stent 10 toenable the brush assembly 230 full mobility over the length of the stent10. In some embodiments, the brush assembly 230 is capable oftranslational movement along the guide rail 310 in combination withrotation and translation of the stent 10.

In another embodiment of the invention, the brush assembly 230 iscoupled to a painting robot, such as one have six axes (three for thebase motions and three for applicator orientation) that incorporatesmachine vision and is electrically driven. Accordingly, the brushassembly 230 can fully rotate around and translate along a stent 10 in astationary position. Alternatively, both the brush assembly 230 and thestent 10 can rotate and/or translate. For example, the brush assembly230 can move for alignment with a strut of the stent 10 while the stent10 can move during coating after alignment, vice versa, or a combinationof both.

In any of the above-mentioned embodiments, the coating process can becontinuous, i.e., the brush assembly 230 can move along and coat theentire stent 10 without lifting off of the stent, or moveintermittently, i.e., coating a first section of the stent 10,optionally lifting off and then aligning with a second section of thestent 10, and coating that second section. The second section may beadjacent to the first section or located a distance from the firstsection.

FIG. 4A, FIG. 4B, FIG. 4C, FIG. 4D, FIG. 4E, and FIG. 4F are diagramsillustrating the brush assemblies 230 a-230 d of the stent coatingapparatuses 200 and 300 according to embodiments of the invention. Thebrush assembly 230 a of FIG. 4A can be coupled to a brush module 400that can be coupled to a mouth of the needle 220. The brush module 400comprises a spongy or porous material that enables a coating substanceto travel through the module 400 (e.g., a mesh plate) onto the brushassembly 230 a. The brush assembly 230 a comprises a plurality of fibersor bristles made of any suitable material that enables the flow of thecoating substance. In an embodiment of the invention, the bristles canbe made from polymer (e.g., rubber), glass, pig bristle, metal fibers,ultra-fine non-absorbent or absorbent fibers, etc. The fibers of thebrush assembly 230 a can be coupled to the module 400 by stringing thefibers through the pores of the module 400. In another embodiment of theinvention, the fibers can be inserted directly into the mouth of theneedle 220 without a module 400 and the mouth of the needle 220 is thenmechanically compressed to hold the fibers in place. Any componentincluding the needle 220, brush module 400 and brush assembly 230 can bedisposable so as to allow a user to use different materials, for examplefor construction of a tri-layer coating such that at least two of theprimer, drug/polymer, and topcoat layers are made from differentmaterials.

The number of fibers in the brush assembly 230 a can vary from a singlefiber (e.g., the brush assembly 230 b having a single fiber centered inthe mouth of the needle 220) to a plurality of fibers (e.g., hundreds).The lengths of the fibers vary based on the length of the stent strut12. The length, number, and fiber material also vary based on theviscosity of the coating substance, the rate of application, the patternof the stent, among other factors. The fibers can be long enough suchthat during the brush process, the fibers can drag along the surfacebeing coated. Alternatively, the fibers can be short enough so as to beless pliable to prevent bending or dragging the fibers. A combination ofthe two embodiments can also be used. For example, the fibers onopposing edges can be long enough to drag on the sidewalls while thefibers on the middle segment are thicker or made from more rigidmaterial so as to prevent dragging of the fibers during the applicationprocess. Alternatively, the fibers of middle segment can be more pliantwhile the fibers at the opposing edges can be rigid.

In an embodiment of the invention, fiber length varies from about ⅛ inchto about 1 inch. In one embodiment, the fiber diameter is about 0.004inches. As shown in FIG. 4D-FIG. 4F, the length of the fibers in thebrush assembly 230 d can vary from each other. Accordingly, when theneedle 220 is aligned with stent strut 12, longer fibers extend down thesidewalls of the stent strut 12 while shorter fibers extend along theoutside surface of the stent strut 12, thereby enabling coating of boththe outer surface and the sidewalls of the stent strut 12. For example,as shown in FIG. 4E, a cross section of the needle 220 with brushassembly 230 d is shown. The lengths of the fibers are represented bytheir diameter and as such, fibers aligned with the sidewalls of thestrut 12 are longer than fibers aligned with the abluminal surface ofthe strut 12. (The diameters of the fibers in FIG. 4E do not representthe relative width of the fibers although in some embodiments, widths ofthe fibers can be different).

Referring in more detail to FIGS. 4E and 4F, as best illustrated, thearea populated by shorter fibers of the middle portion of the brushassembly 230 d are bounded by the longer fibers at two of the endregions of the brush assembly 230 d, which in effect provides apassageway or channel through the brush assembly 230 d. The width ofthis channel can be designed so as to be equivalent or generallyequivalent to the width of a strut being coating. Accordingly, duringthe coating process, a strut fits between the longer fibers as the brushis guided across the strut. With interchangeable components, a user canselect a brush that is compatible with a width of a given strut.

As shown in FIG. 4C and FIG. 4D, embodiments of the invention caninclude brush assemblies 230 c and 230 d wherein fibers of theassemblies are solely attached to perimeter (circumference) of theneedle 220 mouth. Accordingly, the module 400 is not required. In anembodiment of the invention, a brush assembly can include fibers coupledto both a module 400 and to the perimeter of the needle 220 mouth.

FIG. 5 is a diagram illustrating the brush assembly 230 a coating astent strut 12. During operation of the system 200 or 300, the opticalfeedback system 270 causes the alignment of the needle 220 with a stentstrut 12. The optical feedback system 270 then causes the reservoir 210to dispense a coating substance to the needle 220 to the brush assembly230 a. In addition, the optical feedback system 270 can also cause theatomizer 240 to supply atomizing air to the needle 220 during dispensingof the coating substance.

In an embodiment of the invention, the brush assembly 230 a is alignedwith the stent strut 12 such that fibers of the brush assembly 230 aextend along the full depth of the sidewalls of the strut 12, therebyenabling coating of the stent strut 12 abluminal surface as well as thesidewalls. In another embodiment of the invention, the needle 220 ispositioned so that the fibers of the brush assembly 230 a only extend tothe abluminal surface of the stent strut 12, thereby coating only theabluminal stent strut 12 surface and not the sidewalls of the stentstrut 12.

Further, as can be seen in FIG. 5, the coating can produce a differentcolor on the stent strut 12, thereby enabling the optical feedbacksystem 270 to determine if the strut 12 has not been adequately coatedbased on a color change. In an alternative embodiment of the invention,the optical feedback system 270 can measure a change in reflectivity ofthe stent strut 12 and/or other parameters.

FIG. 6 is a flowchart illustrating a method 600 of coating an abluminalstent surface. In an embodiment of the invention, the system 200 or 300can implement the method 600. First, an image of the stent 10 iscaptured (610) as the stent 10 is rotated. Based on the captured image,a brush is aligned (620) with a stent strut 12 of the stent 10 viarotation and/or translation of the stent 10 and/or translation of thebrush. A coating is then dispensed (630) onto the brush. In anembodiment of the invention, during the dispensing (630), the coatingcan also be atomized. As the coating is being dispensed (630), the brushand/or stent are moved (640) relative to each other so as to coat atleast a portion of the stent strut 12.

The dispensing is then stopped (645), and an image of at least a portionof the stent that was just coated in captured (650). Using the capturedimage, the coating is verified (660) based on color change, reflectivitychange, and/or other parameters. If (670) the coating is not verified(e.g., the stent strut 12 was not fully coated), then the strut 12 isrecoated (690) by realigning the brush with the strut 12, dispensing thecoating, and moving the brush relative to the strut. Capturing (650) animage and verifying (660) are then repeated.

If (670) the coating is verified and if (680) the stent has beencompletely coated, then the method 600 ends. Otherwise, the method 600is repeated with a different stent strut starting with the aligned(620).

In an embodiment of the invention, the luminal surface of the stent 10can then be coating with a different coating using electroplating orother technique. Accordingly, the abluminal surface and the luminalsurface can coated with different coatings.

While particular embodiments of the present invention have been shownand described, it will be obvious to those skilled in the art thatchanges and modifications can be made without departing from thisinvention in its broader aspects. Therefore, the appended claims are toencompass within their scope all such changes and modifications as fallwithin the true spirit and scope of this invention.

What is claimed is:
 1. A stent coating apparatus comprising: a brushassembly including a plurality of fibers; a stent support configured tocarry a stent at a position in which the stent is in contact with theplurality of fibers; and a dispensing mechanism configured to dispense acoating composition to the plurality of fibers.
 2. The apparatus ofclaim 1, wherein the dispensing mechanism includes a hollow dispensingneedle configured to dispense the coating composition to the pluralityof fibers.
 3. The apparatus of claim 2, wherein the hollow dispensingneedle is coupled to the plurality of fibers.
 4. The apparatus of claim2, wherein the plurality of fibers includes at least one fiber fixed toa perimeter of an outlet of the hollow dispensing needle.
 5. Theapparatus of claim 2, wherein the brush assembly includes a moduleformed of a spongy material, and the module connects the hollowdispensing needle to the plurality of fibers.
 6. The apparatus of claim2, wherein the brush assembly includes a module formed of a porousmaterial, and the module connects the hollow dispensing needle to theplurality of fibers.
 7. The apparatus of claim 1, wherein the brushassembly includes a module formed of a spongy material or a porousmaterial, and the module is configured to convey the coating compositionfrom the dispensing mechanism to the plurality of fibers.
 8. Theapparatus of claim 7, further comprising a device configured to deliverair to the dispensing mechanism at a location upstream of module.
 9. Theapparatus of claim 1, further comprising a device configured to deliverair to the dispensing mechanism.
 10. The apparatus of claim 1, whereinthe dispensing mechanism is configured to atomize the coatingcomposition.
 11. The apparatus of claim 1, wherein the stent support isconfigured to rotate relative to the plurality of fibers.
 12. Theapparatus of claim 1, wherein the brush assembly is configured totranslate relative to the plurality of fibers.
 13. A stent coatingsystem comprising: the stent coating apparatus of claim 1; and a stentcarried on the stent support of the stent coating apparatus.